Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWE-Switch: Extended Adjuvant Endocrine Therapy in Breast Cancer
NCT06223698Phase 3Not yet recruiting
- Sponsor
- Region Örebro län
- Start
- May 2025
- Primary completion
- May 2032
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tamoxifen, letrozole, anastrozole, exemestane in breast cancer, sponsored by Region Örebro län. Planned start May 2025; status: not yet recruiting.
02
Drugs
tamoxifenletrozoleanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06223698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223698.